|
1
|
Knudsen ES, Gopal P and Singal AG: The
changing landscape of hepatocellular carcinoma: etiology, genetics,
and therapy. Am J Pathol. 184:574–583. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Salgia R and Singal AG: Hepatocellular
carcinoma and other liver lesions. Med Clin North Am. 98:103–118.
2014. View Article : Google Scholar
|
|
4
|
Bosetti C, Turati F and La Vecchia C:
Hepatocellular carcinoma epidemiology. Best Pract Res Clin
Gastroenterol. 28:753–770. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Finn RS: Current and future treatment
strategies for patients with advanced hepatocellular carcinoma:
role of mTOR inhibition. Liver Cancer. 1:247–256. 2012. View Article : Google Scholar
|
|
6
|
Song P1, Gao J, Inagaki Y, Kokudo N,
Hasegawa K, Sugawara Y and Tang W: Biomarkers: Evaluation of
screening for and early diagnosis of hepatocellular carcinoma in
Japan and China. Liver Cancer. 2:31–39. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shao YY, Hsu CH and Cheng AL: Predictive
biomarkers of antiangiogenic therapy for advanced hepatocellular
carcinoma: Where are we? Liver Cancer. 2:93–107. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Scott KL, Kabbarah O, Liang MC, Ivanova E
and Anagnostou V: GOLPH3 modulates mTOR signalling and rapamycin
sensitivity in cancer. Nature. 459:1085–1090. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kunigou O, Nagao H, Kawabata N, Ishidou Y
and Nagano S: Role of GOLPH3 and GOLPH3L in the proliferation of
human rhabdomyosarcoma. Oncol Rep. 26:1337–1342. 2011.PubMed/NCBI
|
|
10
|
Li XY, Liu W, Chen SF, Zhang LQ, Li XG and
Wang LX: Expression of the Golgi phosphoprotein-3 gene in human
gliomas: a pilot study. J Neurooncol. 105:159–163. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Romanuik TL, Wang G, Holt RA, Jones SJ,
Marra MA and Sadar MD: Identification of novel androgen-responsive
genes by sequencing of LongSAGE libraries. BMC Genomics.
10:4762009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abraham RT: GOLPH3 links the Golgi network
to mTOR signaling and human cancer. Pigment Cell Melanoma Res.
22:378–379. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zeng Z, Lin H, Zhao X, Liu G, Wang X, Xu
R, Chen K, Li J and Song L: Overexpression of GOLPH3 promotes
proliferation and tumorigenicity in breast cancer via suppression
of the FOXO1 transcription factor. Clin Cancer Res. 18:4059–4069.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin L, Qin Y, Jin T, Liu S, Zhang S, Shen
X and Lin Z: Significance of NQO1 overexpression for prognostic
evaluation of gastric adenocarcinoma. Exp Mol Pathol. 96:200–205.
2013. View Article : Google Scholar
|
|
15
|
Li H, Guo L, Chen SW, Zhao XH, Zhuang SM,
Wang LP, Song LB and Song M: GOLPH3 overexpression correlates with
tumor progression and poor prognosis in patients with clinically N0
oral tongue cancer. J Transl Med. 10:1682012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou J, Xu T, Qin R, Yan Y, Chen C, Chen
Y, Yu H, Xia C, Lu Y, Ding X, Wang Y, Cai X and Chen J:
Overexpression of Golgi phos-phoprotein-3 (GOLPH3) in glioblastoma
multiforme is associated with worse prognosis. J Neurooncol.
110:195–203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hua X, Yu L, Pan W, Huang X, Liao Z, Xian
Q, Fang L and Shen H: Increased expression of Golgi
phosphoprotein-3 is associated with tumor aggressiveness and poor
prognosis of prostate cancer. Diagn Pathol. 7:1272012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang JH, Chen XT, Wen ZS, Zheng M, Deng
JM, Wang MZ, Lin HX, Chen K, Li J, Yun JP, Luo RZ and Song LB: High
expression of GOLPH3 in esophageal squamous cell carcinoma
correlates with poor prognosis. PLoS One. 7:e456222012. View Article : Google Scholar : PubMed/NCBI
|
